(AMPH) Amphastar P - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03209R1032
AMPH: Injectables, Inhalation Products, Intranasal Sprays, Emergency Kits, APIs
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is a bio-pharmaceutical company specializing in the development, manufacturing, and distribution of generic and proprietary injectable, inhalation, and intranasal products. With operations in the United States, China, and France, the company focuses on critical care and emergency medicine, offering a diverse portfolio of products that address acute and life-threatening conditions. Its product lineup includes BAQSIMI, a nasal spray for severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for mild asthma symptoms; and Enoxaparin for deep vein thrombosis prevention and treatment. Additionally, Amphastar provides REXTOVY and Naloxone for opioid overdose reversal, Glucagon emergency kits, and Cortrosyn for diagnostic purposes in adrenocortical insufficiency screening.
The company also manufactures Amphadase, a hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly and topical solution for anesthetic use; Phytonadione injection for newborns; emergency syringe products; morphine injection for patient-controlled analgesia; and Lorazepam injection for surgical procedures. Its portfolio further includes Neostigmine methylsulfate for myasthenia gravis treatment; Isoproterenol hydrochloride for heart block episodes; Ganirelix Acetate for premature luteinizing hormone surge inhibition; Vasopressin for blood pressure management; and Regadenoson for myocardial perfusion imaging. Amphastar also distributes recombinant human insulin APIs and porcine insulin API, while developing generic and biosimilar product candidates, including intranasal epinephrine for allergic reactions.
Founded in 1996 and headquartered in Rancho Cucamonga, California, Amphastar has established itself as a key player in the pharmaceutical industry, particularly in injectable and inhalation technologies. The company’s focus on R&D and its extensive product range position it as a reliable supplier of essential medications for critical care and emergency situations.
Exchange: NASDAQ
Type: common stock
Country Origin: United States
GICS Sub Industry: Pharmaceuticals
Last Price: 24.50
SMA 20: 24.17
SMA 50: 26.78
SMA 200: 38.99
ATR: 1.02
P/E: 7.82
P/E Forward: None
P/B: 1.55
P/S: 1.55
RoE: 21.78
Forecast: Based on the provided data, Amphastar Pharmaceuticals (AMPH) is currently trading at $24.50, slightly above its SMA 20 of $24.17 but below its SMA 50 of $26.78. The stock’s ATR of 1.02 indicates moderate volatility. Fundamentally, the company’s P/E ratio of 7.82 suggests undervaluation compared to industry peers, while its return on equity (RoE) of 21.78 highlights strong profitability. However, the P/S ratio of 1.55 may signal elevated valuations relative to sales. Moving forward, AMPH is likely to experience short-term price consolidation near the SMA 50 resistance level, with potential upside driven by its robust earnings and product pipeline. Investors should monitor technical support at the SMA 20 and fundamental catalysts such as new product approvals or margin expansion.
Additional Sources for AMPH Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
AMPH Stock Overview
Market Cap in USD | 1,164m |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2014-06-25 |
AMPH Stock Ratings
Growth Rating | 19.4 |
Fundamental | 89.1 |
Dividend Rating | 0.0 |
Rel. Strength | -39.1 |
Analysts | 3.83/5 |
Fair Price Momentum | 20.31 USD |
Fair Price DCF | 77.84 USD |
AMPH Dividends
No Dividends PaidAMPH Growth Ratios
Growth Correlation 3m | -85.6% |
Growth Correlation 12m | -60.9% |
Growth Correlation 5y | 76.5% |
CAGR 5y | 5.14% |
CAGR/Max DD 5y | 0.08 |
Sharpe Ratio 12m | -1.08 |
Alpha | -48.78 |
Beta | 0.462 |
Volatility | 48.49% |
Current Volume | 751.6k |
Average Volume 20d | 543.6k |
As of May 09, 2025, the stock is trading at USD 24.65 with a total of 751,566 shares traded.
Over the past week, the price has changed by +3.22%, over one month by +3.79%, over three months by -23.47% and over the past year by -41.60%.
Yes, based on ValueRay Fundamental Analyses, Amphastar P (NASDAQ:AMPH) is currently (May 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 89.07 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AMPH as of May 2025 is 20.31. This means that AMPH is currently overvalued and has a potential downside of -17.61%.
Amphastar P has received a consensus analysts rating of 3.83. Therefor, it is recommend to buy AMPH.
- Strong Buy: 2
- Buy: 1
- Hold: 3
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, AMPH Amphastar P will be worth about 21.9 in May 2026. The stock is currently trading at 24.65. This means that the stock has a potential downside of -11.03%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 38 | 54.2% |
Analysts Target Price | 38 | 54.2% |
ValueRay Target Price | 21.9 | -11% |